CXCR

CXCR antagonists block CXC chemokine receptors, chiefly CXCR4 and the interleukin-8 receptors CXCR1 and CXCR2. CXC chemokine receptor 4 (CXCR4) binds CXC motif chemokine ligand 12 (CXCL12), also called stromal cell-derived factor 1 (SDF-1), and guides the homing of hematopoietic and immune cells. In 1996 CXCR4 was identified as an entry coreceptor for T-cell-tropic human immunodeficiency virus type 1 (HIV-1). Plerixafor and mavorixafor are CXCR4 antagonists used in studies of stem cell mobilization, cell migration and viral entry. CXCR1 and CXCR2 respond to interleukin-8 (CXCL8) and recruit neutrophils, a process studied with navarixin and reparixin.

2 Items

  • SB265610
    Cat. No.
    A14195

    SB265610

    SB 265610 is a nonpeptide, allosteric, inverse agonist of CXCR2 (Kd = 2.51 nM) that prevents receptor activation by binding to a region distinct from the agonist binding site. It does not bind to the related CXCR1 receptor.1 It has been shown to prevent neutrophil chemotaxis both in vitro and in a rat model of hyperoxia-induced lung injury.

    1 mg
    $45.00
    5 mg
    $85.00
    All 8 sizes
  • VUF11211
    Cat. No.
    A59822

    VUF11211

    VUF11211 is an allosteric inverse agonist of the CXCR3 receptor, exhibiting a dissociation constant (Kd) of 0.65 nM. This compound modulates CXCR3 signaling pathways, influencing immune cell migration and activation. VUF11211 is primarily used in research focused on inflammation, autoimmune diseases, and cancer immunotherapy, providing insights into the role of CXCR3 in various pathological conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...